Uncategorized

Landmark Peer-Reviewed Study Demonstrates First-in-Class Percutaneous Platform for Organ-Isolated Delivery Across Multiple Indications ZURICH/SCHLIEREN, Switzerland, December 23, 2025 – DiNAQOR, an innovative health tech group advancing promising early-stage drug development, today announced the publication of a landmark peer-reviewed study in JACC: Basic to Translational Science. The study, titled “Next-Generation Percutaneous Catheter–Based Closed-Loop Perfusion Concept Enables … Read more

Seasoned biotech entrepreneur Dr. Christian Thirion appointed CEO of DiNATEQ AG and Group Chief Strategy & Business Development Officer; Dr. Josef El Andari named Chief Scientific Officer of DiNAQOR AG as the company continues to build and scale next-generation life science ventures. ZURICH/SCHLIEREN, Switzerland, December 22, 2025 – DiNAQOR AG, an innovative health technology group … Read more

Zurich, September 29, 2025 – DiNAQOR AG, a global advanced medicines company builder, today congratulated Siegfried (SIX: SFZN) and its subsidiary DINAMIQS on the successful completion and inauguration of their new cGMP viral vector manufacturing facility in Switzerland. DINAMIQS was established in 2022 and spun out from DiNAQOR as an independent entity in 2023. Since … Read more

ZURICH-SCHLIEREN, Switzerland, May 4, 2023 – DiNAQOR, an innovative genetic medicine company headquartered in Switzerland with subsidiaries in Laguna Hills/California/USA and Hamburg/Germany focused on proprietary human-based tissue drug development and technology to enable organ-specific delivery of gene therapies and other therapeutics, today announced that it will sell a 95% stake in its subsidiary DiNAMIQS to … Read more

Chris Rusconi to serve as Chief Development Officer; Steven Zelenkofske to take role of Chief Strategy Officer as DiNAQOR continues rapid growth

Dinaqor is pleased to announce our participation in several fall conferences.

DiNAQOR announced the launch of DiNAQOR DiNAMIQS, a biomanufacturing subsidiary, that will accelerate development timelines and reduce costs and risk for genetic medicine companies bringing new treatments to market.

DiNAQOR has entered into a research collaboration with Children’s Medical Research Institute (CMRI) in Australia to develop novel bioengineered adeno-associated virus (AAV) capsids to route gene therapy directly to human cardiac muscle.

DiNAQOR has expanded its leadership team by appointing veteran medical device leader Mark Dehdashtian to serve as Executive Vice President, Medical Devices.

DiNAQOR has expanded the company’s board of directors with three new cardiovascular industry and academic experts: Louis G. Lange, M.D., Ph.D.; Steven Zelenkofske, D.O., M.S.; and Silke Rickert-Sperling, M.D.